Production (Stage)
Zevra Therapeutics, Inc.
ZVRA
$8.65
$0.080.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 69.40% | 225.93% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 69.40% | 225.93% | |||
| Cost of Revenue | -1.54% | -40.69% | |||
| Gross Profit | 78.48% | 667.03% | |||
| SG&A Expenses | 20.83% | -0.20% | |||
| Depreciation & Amortization | -0.06% | 4.60% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.18% | -11.43% | |||
| Operating Income | 65.22% | 43.54% | |||
| Income Before Tax | 90.59% | 38.70% | |||
| Income Tax Expenses | -92.31% | -- | |||
| Earnings from Continuing Operations | 91.33% | -7.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 91.33% | -7.57% | |||
| EBIT | 65.22% | 43.54% | |||
| EBITDA | 73.03% | 46.41% | |||
| EPS Basic | 91.43% | 3.83% | |||
| Normalized Basic EPS | 90.68% | 45.56% | |||
| EPS Diluted | 91.43% | 3.83% | |||
| Normalized Diluted EPS | 90.68% | 45.56% | |||
| Average Basic Shares Outstanding | 1.16% | 11.85% | |||
| Average Diluted Shares Outstanding | 1.16% | 11.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||